# AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

- Link: https://www.directorstalkinterviews.com/astrazenecas-voydeya-approved-in-the-us-as-add-on-therapy-for-pnh-patients-with-evh/4121149481
- Published: 2024-04-02T07:25:55+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Voydeya_ (danicopan) has been approved in the US as add-on therapy to ravulizumab
or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with
paroxysmal nocturnal haemoglobinuria (PNH).^(1) _Voydeya_ is a first-in-class, oral,
Factor D inhibitor developed as an add-on to standard-of-care _Ultomiris_ (ravulizumab)
or _Soliris_ (eculizumab) to address the needs of the approximately 10-20% of patients
with PNH who experience clinically significant EVH while treated with a C5 inhibitor.
^(2,3) 

The approval by the US Food and Drug Administration (FDA) was based on positive 
results from the pivotal ALPHA Phase III trial. Results from the 12-week primary
evaluation period of the trial were published in The Lancet Haematology.^(2)

> **Bart Scott, MD, Professor, Division of Hematology and Oncology at the University
> of Washington Medical Center, and Professor, Clinical Research Division at Fred
> Hutchinson Cancer Center, said**: “The approval of _Voydeya_ offers this small
> subset of PNH patients an add-on therapy designed to address EVH, while maintaining
> disease control with _Ultomiris_ or _Soliris_. Terminal complement inhibition 
> with _Ultomiris_ can address the life-threatening complications of PNH, building
> on the efficacy and safety of _Soliris_ established over nearly 20 years.”

> **Marc Dunoyer, Chief Executive Officer, Alexion, said**: “The approval of first-
> in-class, Factor D inhibitor _Voydeya_ marks an important advancement in the treatment
> of PNH and builds on our leadership and commitment to bring forward innovation
> in complement science. As the ALPHA trial suggests, dual complement pathway inhibition
> at Factor D and C5 may be an optimal treatment approach for this subset of patients
> with EVH, enabling them to continue with proven standard-of-care therapy.”

The ALPHA Phase III trial evaluated the efficacy and safety of _Voydeya_ as add-
on to _Ultomiris_ or _Soliris_ in patients with PNH who experienced clinically significant
EVH. Results showed that _Voydeya_ met the primary endpoint of change in haemoglobin
from baseline to week 12 and all key secondary endpoints, including transfusion 
avoidance and change in Functional Assessment of Chronic Illness Therapy – Fatigue(
FACIT-Fatigue) score.^(2) 

Results from the ALPHA Phase III trial showed _Voydeya_ was generally well tolerated,
and no new safety concerns were identified. In the trial, the most common treatment-
emergent adverse events were headache, nausea, arthralgia and diarrhoea.^(2) 

_Voydeya_ has been granted Breakthrough Therapy designation by the US FDA and PRIority
MEdicines (PRIME) status by the European Medicines Agency. _Voydeya_ has also been
granted Orphan Drug Designation in the US, European Union (EU) and Japan for the
treatment of PNH. _Voydeya_ has been approved in Japan and recommended for approval
in the EU. Regulatory reviews are ongoing in additional countries.  

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc.
As a leader in rare diseases for more than 30 years, Alexion is focused on serving
patients and families affected by rare diseases and devastating conditions through
the discovery, development and commercialisation of life-changing medicines. 

**_Voydeya_** **(danicopan)**

_Voydeya_ (danicopan) is a first-in-class oral Factor D inhibitor. The medication
works by selectively inhibiting Factor D, a complement system protein that plays
a key role in the amplification of the complement system response. When activated
in an uncontrolled manner, the complement cascade over-responds, leading the body
to attack its own healthy cells. _Voydeya_ has been granted Breakthrough Therapy
designation by the US Food and Drug Administration and PRIority MEdicines (PRIME)
status by the European Medicines Agency. _Voydeya_ has also been granted Orphan 
Drug Designation in the US, EU and Japan for the treatment of PNH.

_Voydeya_ is approved in the US as add-on therapy to ravulizumab or eculizumab for
the treatment of EVH in adults with PNH.

_Voydeya_ is also approved in Japan for certain adults with PNH in combination with
C5 inhibitor therapy.

Alexion is also evaluating _Voydeya_ as a potential monotherapy for geographic atrophy
in a Phase II clinical trial.

Share on:
